Multiple Breath Washout, a Clinimetric Dataset

 Cystic Fibrosis / Posted 11 months ago

The Multiple breath washout (MBW) test has been established for more than 60 years, but it is not used as frequently used as spirometry, the gold standard of lung function testing. Lung clearance index (LCI) is a result gained from MBW that tells us how clear someone’s airways are. With the improvement of care, many patients now have normal spirometry and so more sensitive markers/outcome measures of disease severity are required to continue to monitor disease and prevent further disease deterioration. Whilst MBW is established as a tool many discrepancies and unknowns still exist, limiting its standardised widespread use. These factors are, differences in equipment, what normal variation and repeatability are, who will benefit the most from utilisation of this test and how well LCI relates to other measures of respiratory disease. This study aims to address these questions.

  • Inclusion Criteria :
    • CF: diagnosed by standard criteria
    • PCD: diagnosed by ciliary beat frequency measurement, ciliary beat pattern analysis or electron microscopy of ciliary ultrastructure, or genetics
    • Non-CF bronchiectasis: CT diagnosis of bronchiectasis and not fulfilling diagnostic criteria for CF or PCD
    • Asthma: as diagnosed by standard diagnostic criteria of British Thoracic Society/Scottish Intercollegiate Guideline Network (BTS/SIGN) guidelines.
    • Persistent bacterial bronchitis defined as a wet cough present for >1 month, usually with bronchoscopic evidence of chronic infection, that resolves with appropriate antibiotic therapy
    • Sleep Disordered Breathing.
    • For healthy volunteers, these will be colleagues and staff contacts (including children) at a participating centre i.e. Royal Brompton Hospital, or will be siblings of patients.
    • Written informed consent (assent from children of appropriate age) obtained.
  • Exclusion Criteria :
    • Positive culture (within the last year of / receiving treatment for Mycobaterium tuberculosis or abscessus (due to cross-infection concerns).
    • Pregnant or breastfeeding.
    • Inability to understand or cooperate with the test(s).
    • Inability to give informed consent, or withdrawal of informed consent.
  • Study start date : 01/05/2017
  • Study end date : 01/03/2021
  • Wales-Based Study Contact : please speak to your clinician

No post found